Lyell LYL845 (Solid Tumors)

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called LYL845 (the study drug) is a safe and effective treatment for your cancer. The study drug is custom-made for each participant from their own tumor tissue.

What is the Condition Being Studied?

Melanoma, Non-Small Cell Lung Cancer (NSCLC), or Colorectal Cancer

Who Can Participate in the Study?

Adults ages 18-75 who:

  • Are diagnosed with melanoma, NSCLC or colorectal cancer
  • Have received at least one round of previous treatment
  • Have tumor tissue that can be surgically removed
  • Have never received treatment with a cellular therapy

For more information about who can join this study, please contact the study team at 919-681-6468

Age Group
Adults

What is Involved?

If you choose to join this study, you will:

  • Undergo surgery to collect your tumor tissue to make the study drug
  • Receive lympho-depleting chemotherapy
  • Take the study drug
  • Have physical exams and blood draws
  • Have imaging scans (CT and/or MRI)
  • Have heart tests (ECG)

Study Details

Full Title
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies
Principal Investigator
Headshot of Brent A. Hanks
Associate Professor of Medicine
Protocol Number
IRB: PRO00112139
NCT: NCT05573035
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate